An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration
- 21 July 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (8) , 12590-12605
Abstract
Low accumulation of anticancer drugs in tumors and serious systemic toxicity remain the main challenges to the clinical efficiency of pharmaceuticals. Pulmonary delivery of nanoscale-based drug delivery systems offered a strategy to increase antitumor activity with minimal adverse exposure. Herein, we report an osimertinib-loaded perfluoro-15-crown-5-ether (AZD9291-PFCE) nanoemulsion, through intratracheal and intravenous delivery, synergizes with 19F magnetic resonance imaging (19F MRI)-guided low-intensity focused ultrasound (LIFU) for lung cancer therapy. Pulmonary delivery of AZD9291-PFCE nanoemulsion in orthotopic lung carcinoma models achieves quick distribution of the nanoemulsion in lung tissues and tumors without short-term and long-term toxic effects. Furthermore, LIFU can trigger drug release from the AZD9291-PFCE nanoemulsion and specifically increases tumor vascular and tumor tissue permeability. 19F MRI was applied to quantify nanoemulsion accumulation in tumors in real time after LIFU irradiation. We validate the treatment effect of AZD9291-PFCE nanoemulsion in resected human lung cancer tissues, proving the translational potential to enhance clinical outcomes of lung cancer therapy. Thus, this work presents a promising pulmonary nanoemulsion delivery system of osimertinib (AZD9291) for targeted therapy of lung cancer without severe side effects.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2015CB931800)
- Natural Science Foundation of Heilongjiang Province (JQ2020H002)
- Harbin Medical University (HMUMIF-21003)
- China Scholarship Council (201908230103)
- National Natural Science Foundation of China (81627901)
- Heilongjiang Province (2019-15)
- National Reform and Development Funds for Local Universities (2020YQ04)
- Heilongjiang Provincial Key Laboratory of Molecular Imaging foundation
This publication has 50 references indexed in Scilit:
- Characterization and Application of a Nose-Only Exposure Chamber for Inhalation Delivery of Liposomal Drugs and Nucleic Acids to MiceJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2013
- Efficacy of intratracheal instillation of a meropenem/perfluorochemical suspension in acute lung injuryPediatric Pulmonology, 2011
- Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistanceProceedings of the National Academy of Sciences, 2010
- Pulmonary versus systemic delivery of levofloxacinPulmonary Pharmacology & Therapeutics, 2008
- Minute dosages of α
ν
β 3 ‐targeted fumagillin nanoparticles impair Vx‐2 tumor angiogenesis and development in rabbitsThe FASEB Journal, 2008
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Multifunctional Nanoparticles for Combining Ultrasonic Tumor Imaging and Targeted ChemotherapyJNCI: Journal of the National Cancer Institute, 2007
- Aerosol delivery of chemotherapy in an orthotopic model of lung cancerEuropean Respiratory Journal, 2005
- Effect of pH, ionic strength and oxygen burden on the chemical stability of EPC/cholesterol liposomes under accelerated conditionsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2000
- Cardio-Respiratory Studies in Patients with Lung TumorsDiseases of the Chest, 1967